CN Patent

CN109843275B — 药物组合物和针对溶酶体贮积症的用途

Assigned to Intrabio Ltd · Expires 2026-04-24 · 0y expired

What this patent protects

本公开内容提供了对溶酶体贮积症(LSD)的治疗，其包括施用乙酰‑亮氨酸或其药学上可接受的盐。

USPTO Abstract

本公开内容提供了对溶酶体贮积症(LSD)的治疗，其包括施用乙酰‑亮氨酸或其药学上可接受的盐。

Drugs covered by this patent

Aqneursa (LEVACETYLLEUCINE) · Intrabio

Patent Metadata

Patent number: CN109843275B
Jurisdiction: CN
Classification: —
Expires: 2026-04-24
Drug substance claim: No
Drug product claim: No
Assignee: Intrabio Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.